NPHS2 antibodies are primarily associated with the study of podocin, a critical protein encoded by the *NPHS2* gene, which is predominantly expressed in podocytes of the kidney glomerulus. Podocin plays an essential role in maintaining the structural and functional integrity of the glomerular filtration barrier. Mutations in *NPHS2* are linked to hereditary forms of steroid-resistant nephrotic syndrome (SRNS), particularly autosomal recessive childhood-onset SRNS. NPHS2 antibodies are widely used in research and diagnostics to detect podocin expression in renal tissues via immunohistochemistry, immunofluorescence, or Western blotting. These antibodies help identify podocyte injury or abnormal podocin distribution, aiding in the diagnosis of genetic or acquired podocytopathies. In clinical settings, detecting *NPHS2* mutations alongside protein expression analysis supports personalized management of nephrotic syndrome. Additionally, NPHS2 antibodies contribute to studies exploring podocyte biology, protein-protein interactions (e.g., with nephrin and CD2AP), and disease mechanisms in experimental models. Notably, while NPHS2-related pathologies are typically genetic, secondary podocin dysfunction may occur in acquired glomerular diseases like focal segmental glomerulosclerosis (FSGS). Research using these antibodies continues to advance understanding of glomerular diseases and potential therapeutic targets.